Published in Ageing Res Rev on May 15, 2010
Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer (2014) 0.92
Medicines management support to older people: understanding the context of systems failure. BMJ Open (2014) 0.85
Practical problems with medication use that older people experience: a qualitative study. J Am Geriatr Soc (2014) 0.82
Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study. PLoS One (2014) 0.82
Potentially inappropriate prescribing in institutionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria. Pharm Pract (Granada) (2012) 0.81
Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev (2012) 0.79
Challenges and opportunities in the design of age-appropriate drug products. Z Gerontol Geriatr (2012) 0.79
Determinants of self-medication with NSAIDs in a Portuguese community pharmacy. Pharm Pract (Granada) (2016) 0.77
Drug-related problems in patients with erectile dysfunctions and multiple comorbidities. Ther Clin Risk Manag (2017) 0.75
Oral drug therapy in elderly with dysphagia: between a rock and a hard place! Clin Interv Aging (2017) 0.75
Individual oral therapy with immediate release and effervescent formulations delivered by the solid dosage pen. J Pers Med (2012) 0.75
Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models. Z Gerontol Geriatr (2014) 0.75
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell (2005) 2.52
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci (2002) 2.24
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
An ancient genome duplication contributed to the abundance of metabolic genes in the moss Physcomitrella patens. BMC Evol Biol (2007) 2.17
A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci U S A (2002) 2.11
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods (2005) 1.93
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Developing a new formulation of sodium phenylbutyrate. Arch Dis Child (2012) 1.77
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A practical note on the use of cytotoxicity assays. Int J Pharm (2004) 1.63
A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci (2007) 1.49
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Mouse phenotyping. Methods (2010) 1.43
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry (2010) 1.39
Performance qualification of an electronic tongue based on ICH guideline Q2. J Pharm Biomed Anal (2009) 1.36
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci (2009) 1.28
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci (2003) 1.17
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine (2008) 1.15
Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm (2011) 1.15
Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol Sci (2009) 1.13
Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet (2005) 1.13
The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J Neurosci (2002) 1.12
The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J (2009) 1.12
Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci (2009) 1.09
Innovations in phenotyping of mouse models in the German Mouse Clinic. Mamm Genome (2012) 1.09
CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol (2010) 1.09
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis (2010) 1.07
An integrated genome research network for studying the genetics of alcohol addiction. Addict Biol (2010) 1.07
Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci (2002) 1.05
Requirement of the RNA-editing enzyme ADAR2 for normal physiology in mice. J Biol Chem (2011) 1.05
Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci (2008) 1.05
Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther (2003) 1.05
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion. Eur J Pharm Biopharm (2011) 1.03
N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology (2011) 1.02
The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A (2011) 1.02
Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology (2005) 1.02
Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm (2004) 1.02
Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology (2008) 1.02
Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci (2005) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Analysis of the mouse transcriptome for genes involved in the function of the nervous system. Genome Res (2003) 1.00
SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One (2013) 1.00
Dissolution testing of hardly soluble materials by surface sensitive techniques: clotrimazole from an insoluble matrix. Pharm Res (2014) 1.00
An antinociceptive role for substance P in acid-induced chronic muscle pain. Proc Natl Acad Sci U S A (2011) 0.99
Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa. Nanotoxicology (2011) 0.99
Educational paper: formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr (2012) 0.98
Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver Int (2011) 0.98
Incongruent pattern of neurokinin B expression in rat and mouse brains. Cell Tissue Res (2005) 0.97
CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci U S A (2012) 0.97
Modulation of alcohol and nicotine responses through the endogenous opioid system. Prog Neurobiol (2009) 0.97
The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. Int J Nanomedicine (2011) 0.96
Analysis of the cellular expression pattern of beta-CGRP in alpha-CGRP-deficient mice. J Comp Neurol (2004) 0.96
The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol Psychiatry (2008) 0.95
The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum (2009) 0.95
High mobility group N proteins modulate the fidelity of the cellular transcriptional profile in a tissue- and variant-specific manner. J Biol Chem (2013) 0.95
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol (2012) 0.94
An fMRI study on the acute effects of exercise on pain processing in trained athletes. Pain (2012) 0.94
Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci (2012) 0.93
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol (2010) 0.93
Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology (Berl) (2004) 0.92
Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int J Neuropsychopharmacol (2008) 0.92
Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One (2012) 0.92
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood (2007) 0.92
Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol (2009) 0.92
Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol (2005) 0.92
Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release (2006) 0.92
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci (2012) 0.91
Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child (2012) 0.91
Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6. Eur Neuropsychopharmacol (2009) 0.90
Peroxisomes in human and mouse testis: differential expression of peroxisomal proteins in germ cells and distinct somatic cell types of the testis. Biol Reprod (2007) 0.90
Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med (2009) 0.90
Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol (2008) 0.90
Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol (2011) 0.89
Detection of trace crystallinity in an amorphous system using Raman microscopy and chemometric analysis. Eur J Pharm Sci (2010) 0.89
Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 ( 416insG ) mice. Mamm Genome (2009) 0.89
Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. Neuropharmacology (2009) 0.89
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm (2005) 0.88
Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release (2005) 0.87
Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm (2013) 0.87
Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol (2008) 0.87
Lineage conversion of murine extraembryonic trophoblast stem cells to pluripotent stem cells. Mol Cell Biol (2011) 0.87